Literature DB >> 2930627

Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.

A T McGown1, B W Fox.   

Abstract

The novel agents amphethinile and combretastatin A4 are shown to be very similar to colchicine in their interactions with purified tubulin. All three agents can inhibit tubulin assembly at similar treatment levels and have comparable affinity constants for tubulin. Amphethinile and combretastatin A4 are capable of displacing colchicine but not vinblastine from tubulin. A comparison of the structures of these agents shows that whereas colchicine and combretastatin A4 contain a trimethoxybenzene group (a moiety also found in other colchicine-like agents such as podophyllotoxins and steganacin) no obvious similarity is seen for amphethinile. The three-dimensional structures of these agents, determined from either crystallographic data or by energy minimization procedures, show, however, that all three agents consist of two planar, or almost planar, ring systems which are tilted with respect to each other. Using computer graphic techniques it can be shown that their ring systems are superimposable and that the planar sections of each molecule are at an angle of 50-60 degrees to each other. It is proposed that the angular bicyclic structure of these agents is one determining factor for their efficient binding to tubulin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2930627

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  18 in total

1.  Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review.

Authors:  Bryan T Oronsky; Jan J Scicinski; Tony Reid; Susan Knox
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

2.  Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines.

Authors:  A T McGown; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy.

Authors:  Zhe Wang; Wai-Keung Chui; Paul C Ho
Journal:  Pharm Res       Date:  2010-11-06       Impact factor: 4.200

Review 4.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

5.  Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.

Authors:  Narsimha Reddy Penthala; Hongliang Zong; Amit Ketkar; Nikhil Reddy Madadi; Venumadav Janganati; Robert L Eoff; Monica L Guzman; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2014-12-29       Impact factor: 6.514

6.  Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

Authors:  Loïc Vincent; Pouneh Kermani; Lauren M Young; Joseph Cheng; Fan Zhang; Koji Shido; George Lam; Heidi Bompais-Vincent; Zhenping Zhu; Daniel J Hicklin; Peter Bohlen; David J Chaplin; Chad May; Shahin Rafii
Journal:  J Clin Invest       Date:  2005-10-13       Impact factor: 14.808

7.  Efficient Synthetic Methodology for the Construction of Dihydronaphthalene and Benzosuberene Molecular Frameworks.

Authors:  Deboprosad Mondal; Haichan Niu; Kevin G Pinney
Journal:  Tetrahedron Lett       Date:  2018-12-16       Impact factor: 2.415

8.  An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.

Authors:  Rajendra P Tanpure; Clinton S George; Madhavi Sriram; Tracy E Strecker; Justin K Tidmore; Ernest Hamel; Amanda K Charlton-Sevcik; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2012-06       Impact factor: 3.597

9.  The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.

Authors:  Isabelle Petit; Matthias A Karajannis; Loic Vincent; Lauren Young; Jason Butler; Andrea T Hooper; Koji Shido; Hermann Steller; David J Chaplin; Eric Feldman; Shahin Rafii
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

Review 10.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.